Comparative Pharmacology
Head-to-head clinical analysis: EULEXIN versus NILANDRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EULEXIN versus NILANDRON.
EULEXIN vs NILANDRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone to androgen receptors in target tissues, thereby blocking androgen action.
Competitive inhibitor of androgen binding to androgen receptors, reducing androgen-mediated growth of prostate cancer cells. Also inhibits testicular and adrenal androgen synthesis.
250 mg orally three times daily (every 8 hours).
300 mg orally three times a day.
None Documented
None Documented
5-6 hours for flutamide; 8-10 hours for active metabolite 2-hydroxyflutamide; requires three times daily dosing
Terminal elimination half-life: 7-8 hours; clinically relevant for twice-daily dosing.
Renal: 28% (as unchanged drug and metabolites, mainly 2-hydroxyflutamide), Biliary/Fecal: 4.2% (as metabolites)
Renal: 55-60% as unchanged drug; fecal: 20-30% as metabolites; biliary: minor (<10%).
Category C
Category C
Antiandrogen
Antiandrogen